EBVALLO™ (tabelecleucel)

About Atara Biotherapeutics

Atara Biotherapeutics is focused on unleashing the power of the body's immune system by developing next-generation, allogeneic T-cell immunotherapies. Its core technology utilizes donor-derived EBV T cells, which do not require T-cell receptor or HLA gene editing, enabling the creation of scalable, off-the-shelf treatments. The company has achieved the landmark approval of EBVALLO™ for post-transplant lymphoproliferative disease and is advancing a pipeline of next-generation CAR T candidates for B-cell cancers and autoimmune diseases. Atara's strategy centers on overcoming the limitations of current autologous cell therapies through rapid delivery and scalable manufacturing.

Therapeutic Areas